April 2009

TABLE OF CONTENTS

Growth or Recession: Selling Solutions is the Answer

Derrek G. Hennecke, MBA, profiles in this 6-part series, unique strategies for building lasting competitive advantages. 

Ocular Drug Delivery: Expanding the Field of Vision

Frost & Sullivan Analyst Misty Hughes believes that achieving optimum therapeutic drug levels to more effectively treat many ocular conditions will necessitate improvements in drug delivery.

 

A Look at Fast-Dissolving Drug Delivery Systems

Bill Martineau, MBA, provides a brief overview on the two major types of delivery systems that incorporate fast-dissolving properties to speed up the onset of therapeutic actions imparted by oral pharmaceutical formulations.

                         

The Evolution of Adhesives: From Transdermal Drug Delivery to Other Novel Delivery Formats

William G. Meathrel, PhD, reviews the evolution and formulation challenges of adhesive technologies from their use in passive transdermal drug delivery systems to their use in cutting-edge active delivery devices and novel forms for alternative site delivery.

 

Design & Development of Novel Osmotic Tablets for Glipizide Controlled Delivery

Jayvadan Patel, PhD; Mukesh Patel, PhD; and Jayant Chavda, PhD; develop a new squeeze-type osmotic tablet to completely deliver glipizide, a BCS Class II drug, in a zero-order manner over an extended period.

 

Inovio Biomedical: Delivering the Potential of DNA Vaccines

Drug Delivery Executive: Avtar Dhillon, MD, President and CEO of Inovio Biomedical, discusses his company’s unique technology and its role in the next generation of vaccines.

 

Colon-Specific Delivery: Histomorphological Analysis & Targeted Prodrug Approach

Anil K. Philip, PhD, explains how a CSDD system through colon-specific prodrug activation may be accomplished by the utilization of high activity of certain enzymes at the target site, relative to non-target tissues for prodrug to drug conversion.

 

Specialty Pharma & Biotech Driving Current CRO Growth & Trends
Contributor Cindy H. Dubin puts the tough questions to some of the industry’s leading CROs about attracting Specialty Pharma partnerships, expanding their global presence, and the shift in IT decision-making.                                                                          

 

Somnus Therapeutics: Taking On the Top Unmet Need in the Blockbuster Insomnia Market

Executive Summary: Gary Cupit, CEO of Somnus Therapeutics, says that while his company’s focus is on the insomnia market, these economic times call for a broader view of product development.

 

DEPARTMENTS

 

Market News & Trends

 

Advanced Delivery Devices

Painless Intradermal Delivery of Insulin: The Novel ClickSoft Microinjection Device

 

Excipient Update

Silicified Microcrystalline Cellulose as a Multifunctional Pharmaceutical Excipient

 

Technology Showcase

 

External Delivery

The Fallacy of Retention Bonuses

COVER

FEATURES